Year-End Cheer For Glenmark As Ryaltris To Debut In Australia

Glenmark is ending 2019 on a buoyant note, with its rhinitis therapy getting the go-ahead in Australia. Though not seen as a huge commercial opportunity in the island continent, the clearance augurs well for the product’s overall trajectory.

3D_Australia
Australia To Be First Market Globally For Ryaltris • Source: Shutterstock

Glenmark Pharmaceuticals Ltd.’s rhinitis therapy Ryaltris (olopatadine HCl/mometasone furoate) has been approved in Australia, the first market where the fixed‐dose combination nasal spray is expected to be launched next year.

Glenmark said that its partner Seqirus Pty. Ltd. had received marketing clearance for Ryaltris from the Therapeutic Goods Administration (TGA),...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Focus On Asia

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

More from Scrip